Oral antiviral therapy for HBeAg negative chronic hepatitis B: Better stop or continue?

Gut

Volumn 64, Issue 4, 2015, Pages 526-528

  Lampertico, Pietro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TENOFOVIR; VIRUS DNA;

DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG USE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FIBROSIS; MONOTHERAPY; NONHUMAN; NOTE; PORTAL HYPERTENSION; PRIORITY JOURNAL; RELAPSE; SEROCONVERSION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS REPLICATION;

HUMANS;

EID: 84924350874     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307596     Document Type: Note

References (16)

1. Chang TT, Lai CL, Yoon SK, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
2. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-75.
3. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in real-life settings: from clinical trials to clinical practice. J Viral Hep 2012;19:377-86.
4. Papatheodoridis GV, Dalekos G, Sypsa V, et al. Page-B: risk score for hepatocellular carcinoma (HCC) development in caucasian chronic hepatitis B (CHB) patients receiving entecavir (ETV) or tenofovir (TDF). J Hepatol 2014;60(Suppl):S435.
5. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52.
6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2012;57: 167-85.
8. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-61.
9. Invernizzi F, Lampertico P, Mangia G, et al. Portal hypertension but not HCC risk is attenuated in compensated cirrhotics following 10 years of treatment with nucleos(t)ide analogs. J Hepatol 2014;60(Suppl):S429-30.
10. Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014;63:1325-32.
11. Seto W-K, Hui AJ, Wong VW-S, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut 2015;64:667-72.
12. Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888-96.
13. Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012;143:629-36.
14. He D, Guo S, Chen W, et al. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative. BMC Infect Dis 2013;13:458.
15. Kim YJ, Kim K, Hwang SH, et al . Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients. Clin Mol Hepatol 2013;19:300-4.
16. Chen C-H, Lu SN, Hung CH, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol Published Online First: 2 May 2014.